Background
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic inflammatory condition characterised by ANCA production and serum positivity that injures small- to medium-sized blood vessels in body organs [
1]. AAV conditions include microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA) [
2‐
6]. Although AAV with only renal lesions is called renal-limited vasculitis (RLV), RLV is usually interpreted as an organ-limited variant of MPA [
7‐
9]. AAV often presents not only as rapidly progressive glomerulonephritis in the kidneys but also as interstitial pneumonia, alveolar haemorrhage, cranial nerve lesion, and others [
2‐
5,
7,
8], with some of these being life-threatening. Therefore, immediate confirmation of the diagnosis and initiation of effective induction therapy are needed.
AAV is caused by autoimmune mechanisms and its treatment typically includes immunosuppressive agents (such as cyclophosphamide and rituximab) and combined glucocorticoid therapy for induction immunosuppressive therapy [
10]. The main ANCA target antigens are myeloperoxidase and proteinase 3 [
11]. Recently, ANCAs have been reported to activate neutrophils directly, which then adhere to and penetrate the vessel walls [
12]. The activated neutrophils release various inflammatory mediators and factors that stimulate the alternative complement pathway [
13], as well as neutrophil extracellular trap (NETs) formation [
14].
Thus, as ANCAs appear to be associated with the progression of severe vasculitis lesions, eliminating ANCAs and their various mediators by plasma exchange (PE) may be an effective addition to immunosuppressive therapy for AAV patients [
15]. However, since PE replaces a large amount of the patient’s plasma with almost the same amount of albumin preparation or fresh frozen plasma, side effects such as hypocalcaemia, hypo- or hypervolaemia, and anaphylactoid reactions are reported [
16].
Several randomised controlled trials (RCTs) have investigated the efficacy and safety of PE for AAV. Moreover, the results of the largest RCT, the PEXIVAS study, were recently published [
17]. Further, some systematic reviews of such clinical questions have been conducted previously [
18‐
20]. However, since most of their study search occurred over 5 years ago, the results of recent studies, such as the PEXIVAS study, were not included [
18,
19]. Moreover, the latest review’s search strategy did not include all three AAV subtypes, and the eligibility criteria might have excluded AAV without renal lesions [
20]. AAV is dealt with as one disease entity in many guidelines, regardless of its subtype or lesion location [
3‐
5]; hence, a review subsuming all the AAV types is more useful for guideline developers and clinicians.
Here, we performed a systematic review and meta-analysis of RCTs, with a search scope, including MPA, GPA, and EGPA, to assess the efficacy of PE for AAV. The primary outcomes were mortality, clinical remission (CR), and adverse events (AEs).
Methods
The present systematic review and meta-analysis were performed in accordance with the Cochrane Handbook for Systematic reviews and Interventions. This study was reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement for health care interventions as shown in the additional PRISMA file (Additional file
1). The detailed method of this review is in the study protocol as shown in the additional data file (Additional file
2).
Search strategy
We searched MEDLINE, PubMed, Embase, CENTRAL (Cochrane Central Register of Controlled Trials) databases to identify the studies. The final search date was 17 June 2020. The search strategies used with each database were created under the guidance of a Cochrane information specialist and are described in Additional file
3. We searched
ClinicalTrials.gov and the World Health Organization trials portal to identify ongoing or unpublished trials.
Study selection
Two reviewers (YY and MH) independently screened for RCTs comparing PE with non-PE in AAV patients. Only RCTs that met the following criteria were included in this review.
Participants
Inclusion criteria included all studies that are primarily on AAV in participants aged ≥ 18 years who are diagnosed with AAV, including confirmed GPA (formerly Wegener’s granulomatosis; WG), EGPA (formerly Churg-Strauss syndrome; CSS), MPA, and RLV [
6].
Exclusion criteria were patients with other types of vasculitis, including anti-glomerular basement membrane disease.
Intervention and comparator
This review considered studies that evaluated the effectiveness of PE in AAV.
Intervention: PE group
Comparator: non-PE or sham PE group
We included any method of PE treatment or PE dose. In reference to the American Society for Apheresis guidelines, PE was defined as typical PE, double filtration plasmapheresis, or selective PE [
21‐
23]. Immunoabsorption treatment was excluded [
24].
We included studies whose design could be used to evaluate the effect of PE alone, i.e. PE + treatment A compared with non-PE (or sham PE) + treatment A. If PE + treatment A was compared with non-PE (or sham PE) + no other treatment or if PE was compared directly with another treatment, we assessed those results separately.
In the case of a study with a mixture of eligible and ineligible participants, it was included if > 80% of all the participants were considered eligible.
Data abstraction
Information regarding the study design, detailed content of intervention and comparator, number of participants, inclusion and exclusion criteria, and clinical outcomes were obtained. Missing data were requested from the corresponding author via email. The quality of the abstracted studies was assessed using Cochrane Collaboration’s tool for assessing the risk of bias (the Cochrane ‘Risk of bias’ tool 2) [
25]. For the assessment of reporting bias, we planned to check using funnel plots if 10 or more studies were included; however, since the studies were not up to 10, the assessment was not performed.
Outcomes
The primary outcomes were (1) mortality, (2) CR (as defined by the study’s authors, typically as the complete absence of disease activity determined by the Birmingham Vasculitis Activity Score [BVAS]), and (3) AEs. The secondary outcomes were (1) renal failure (end-stage renal disease [ESRD], the composite of ESRD or death, improvement in renal function or changes in serum creatinine level); (2) disease flare/relapse (as defined in the study); (3) health-related quality of life (QOL); and (4) disease damage according to the Vasculitis Damage Index (VDI).
Statistical analysis
Data were analysed from June to July 2020. All the analyses were carried out using Review Manager 5, Version 5.3 (Copenhagen, Nordic Cochrane Centre, Germany). Dichotomous data were analysed using risk ratios (RR) with 95% confidence intervals (CIs). Continuous data were analysed as mean differences with 95% CIs when the measurements used the same scale. The pooled RR was calculated by the random-effect model using the Mantel-Haenszel method. For the assessment of statistical heterogeneity, we utilised the I2 statistic. Significant heterogeneity was defined as I2 statistics value of above 50%. Two-sided P < 0.05 was considered significant and was calculated using the z test of the null hypothesis indicating that there was no average effect in the random-effect model of PE vs. non-PE.
Subgroup analysis and sensitivity analysis
We undertook the following subgroup analyses in the studies that had the following available data: types of AAV (only MPA or GPA) and PE conditions, while those of ANCA status and localisation of lesions could not be performed.
We performed sensitivity analyses on primary outcomes to determine if a high risk of bias that occurred in some included studies affected the study results by the exclusion of studies at a high risk of bias, exclusion of trials with ≤ 10 events, and exclusion of cluster RCTs, and by comparing fixed- vs. random-effects pooled estimates.
Discussion
We conducted a review of multiple RCTs investigating the efficacy of PE for AAV. This is a novel review in that the search strategy covers all three AAV types, the target population was not limited to those with renal lesions, and the results of the latest and largest RCT, PEXIVAS, were included.
In the current review, when comparing the incidence of primary outcomes between PE and non-PE groups (both PE vs. no PE and PE vs. pulse steroid), there was no significant difference. The latest observational study using real-world data also showed similar results that the additional PE had no benefit [
35]. Although there are lots of pathological dogmas that AAV are autoimmune diseases driven by ANCA, this result could raise a question of whether ANCA plays a major role in the pathogenesis of AAV, since PE directly removes ANCA from patients’ serum. There is also evidence suggesting that ANCA might not be majorly involved in the pathogenesis of AAV. First, most patients with ANCA do not develop AAV [
36]. Second, the correlation between ANCA titers and the disease activity of AAV remains elusive [
37]. Third, ANCA might not be the main reason for the forward loop of NETosis fuelling inflammation in AAV and could just be a marker of leukocytoclastic inflammation in small blood vessels [
38]. Forth, improvement of AAV by rituximab could better fit with the hypothesis that circulating B cell plays an important pathogenic role, rather than plasmocytes, which is the major source of antibodies including ANCA [
39]. Fifth, cyclophosphamide and its metabolites also target endothelial cells, which might not only be the victims in AAV but also the culprits [
40]. Further elucidation of the pathophysiology of AAV is desired in the future. On the other hand, as a remarkable point with the secondary outcomes, PE was associated with a statistically significant reduction in the ESRD (death-censored) development rate in the early stage of treatment. These results were observed in both PE vs. no PE and PE vs. pulse steroid analyses. There is a possibility that a selection bias may be involved in this reduction in ESRD rate because recent data (< 1 year after allocation in PEXIVAS, which is the largest RCT in this review) were not available. However, the Kaplan-Meier curve showing the incidence of the primary endpoint (ESRD or death) in the PEXIVAS report [
17] indicated fewer occurrences of the endpoints in the PE group than in the no PE group in the early stage of treatment. In the Kaplan-Meier plot, the two curves met at 2–3 years after the start of observation. Therefore, there is an impression that the results of PEXIVAS were consistent with those of other studies. PE might suppress early renal injury by removing humoral factors that exacerbate renal injury of AAV.
Although PE has long been used as one of the treatment options for AAV, so far, its therapeutic indication needs to be thoroughly considered once again based on the results of this review. It is not recommended to actively perform PE for all AAV patients, because PE showed no benefit in terms of the primary outcomes of this study. Further, there are other disadvantages, including high treatment costs [
41]. On the other hand, PE may be a treatment option for AAV patients with a high risk of early renal failure, since it suppressed ESRD in the early stage of treatment. However, patients who developed ESRD in the early stage of treatment (at 3 months; PE vs. no PE) were only 24% (10/41) of the no PE group and merely 13% (11/84) of all patients. It could be worth to retrospectively study the baseline profile of patients who developed early renal failure and responded to treatment to try and restrict the use of PE in such patients. Moreover, since the statistically significant difference of ESRD between the two groups disappeared in the long run, it needs to be evaluated whether early stage-limited ESRD suppression is clinically meaningful from various viewpoints, such as QOL and treatment cost.
The search results of this review revealed that there was no RCT that evaluated the effect of PE on EGPA. Although Guillevin et al. performed RCTs, including CSS (currently EGPA) patients, only approximately 20% of the participants had CSS, while a majority of the patients had polyarteritis nodosa [
42,
43]. Therefore, evaluating the efficacy of PE for CSS from those results was considered difficult; thus, those studies were excluded from the current review. As a side note, Guillevin et al. extracted the data of 32 patients diagnosed with MPA and CSS (28 MPA, 4 CSS) from the results of these RCTs and performed a sub-analysis that integrated the results [
34]. They also concluded that PE has no added benefit. An RCT in a large population of EGPA patients is required in the future.
This is the first review after the detailed results of PEXIVAS were published [
17]. Although PEXIVAS targeted patients with severe AAV, only 14% (99/704) of the patients died and only 20% (138/704) reached ESRD during the observation period. Further, fewer hard outcomes were noted than those in other RCTs. In this review, we were able to analyse not only the primary outcome but also other secondary outcomes of PEXIVAS such as relapse and QOL indicators, and the breakdown of AEs in more detail compared to other previous reviews.
Since the diagnostic criteria of vasculitis syndrome have changed over time [
6,
7], when conducting a systematic review, sufficient attention is necessary for setting the eligibility criteria. In this review, we set the eligibility criteria to include only patients with a definite diagnosis of AAV (MPA, GPA, or EGPA [+RLV]), similar to another previous review protocol [
44]. Therefore, patients having old diagnoses, such as idiopathic rapidly progressive glomerulonephritis and idiopathic crescentic glomerulonephritis [
33,
45], which do not meet the current diagnostic criteria and that may include non-AAV patients, were excluded [
46‐
50]. Therefore, we could reduce the possibility that non-AAV patients were included in this review, and that the results are now more reliable and easier for the clinicians to understand.
This review has limitations. Local search sources, such as Japanese and Chinese sources, were not searched. In addition, since 2 of the included studies included < 20% ineligible patients, the PE vs. no PE meta-analysis included only a few patients (10 [1.2%]) who were not diagnosed with AAV. These might have involved a selection bias. Finally, the definitions of CR and improvement in renal function differed among studies, which might involve an information bias.
Conclusions
We performed the latest review to assess the efficacy of PE for AAV, which included all AAV subtypes (MPA, GPA, and EGPA) in the search scope. In AAV patients, performing PE was not significantly associated with the risk of primary outcomes, mortality, CR, and AEs. In the secondary outcomes, it was suggested that PE may be effective in suppressing ESRD in the early stages of treatment. None of the RCTs verified the effect of PE on EGPA, and this should be investigated in the future.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.